Research
Protease, Microenvironment and Cancer : E. Liaudet-Coopman

RESEARCH TOPICS

Our overall goal is to understand how the breast tumor microenvironment, now recognized as an important contributor to the progression of malignancy and metastasis, is altered by factors secreted by cancer and stromal cells, such as proteases, matrix proteins, or growth factors. One of our main objectives concern the immunotargeting of the protease cathepsin D secreted into the tumor microenvironment of breast cancer (using human antibody and antibody-drug conjugate (ADC)) in different mouse models, the detailed elucidation of the anti-tumor mechanisms, and combinatory therapy with chemotherapy and immune checkpoint inhibitors. We will also use the expertise acquired over the past several years to address fundamental questions about the non-classical signaling function of proteases in breast cancers with emphasis on substrates from the extracellular matrix. We will develop preclinical mouse models of breast cancer for studies on the cross-talk between epithelial and stromal cells during breast cancer progression in integrated systems.

                                                    More

MAIN PUBLICATIONS

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy P-J, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br. J. Cancer. 2018;119(1):76-79. doi:10.1038/s41416-018-0142-6

Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul M-A, Mondon P, Barret J-M, Mathis G, Prost J-F, Pèlegrin A, Chardès T Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3. Mol. Cancer Ther.. 2017;16(7):1312-1323. doi:10.1158/1535-7163.MCT-16-0886

Bach A-S, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares L, Reinheckel T, Meurice G, Kaiser F, Gespach C, Liaudet-Coopman E Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells. Oncotarget. 2015;6(29):28084-28103. doi:10.18632/oncotarget.4394

Sebti S, Prébois C, Pérez-Gracia E, Bauvy C, Desmots F, Pirot N, Gongora C, Bach A-S, Hubberstey A, Palissot V, Berchem G, Codogno P, Linares L, Liaudet-Coopman E, Pattingre S BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy. Proc. Natl. Acad. Sci. U.S.A.. 2014;111(11):4115-4120. doi:10.1073/pnas.1313618111


Team

Team Leader :
Emmanuelle Liaudet-Coopman

 

Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle

34298 Montpellier cedex 5

Tél. 33 (0)4 67 61 24 23
Fax 33 (0)4 67 61 37 87
emmanuelle.liaudet-coopman@inserm.fr

Discover the team


   

 

partners / funding


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés